Weight‑Loss Injections Could Thin Beer Sales, Heineken Warns as MPs Urge NHS to Boost Jabs

Heineken has sounded the alarm to British pubs that the boom in weight‑loss drugs such as Wegovy could trim the nation’s appetite for beer and cider. The brewer’s warning comes with a wry observation: the only thing thinner than a pint these days might be its sales forecast.

At the same time, a chorus of back‑bench MPs has taken to the Commons floor urging the NHS to hand out more of those very same injections. Their argument is simple – if waistlines are shrinking faster than the foam on a half‑pint, the health service should be the one supplying the syringes.

Heineken’s concern isn’t just about a few lost pints; it’s about the ripple effect on ciders, ales and the broader pub‑culture that has long been the social glue of the UK. A quieter bar, they note, means quieter cash registers and, inevitably, quieter conversations about the weather.

MPs have pointed out that the current NHS plan aims to treat just 6% of eligible patients with the drug Mounjaro by 2028 – a figure they describe as “unambitious”. They are pressing for a more aggressive rollout, which, while intended to curb obesity, could also turn the nation’s drinking habits into a lower‑calorie affair.

The brewing industry’s response reads like a cautionary tale for any sector that relies on indulgence: if people stop reaching for a pint after their morning injection, profit margins could end up as flat as a diet soda.